

Bioresonance therapy with children suffering from allergies – an overview of clinical reports

Poster presented during the 2nd European Congress for Integrative Medicine – Berlin, November 20 – 21.2009

Dr. rer. nat. Michael Galle
Institut für Biophysikalische Medizin
Achatstraße 12a
55743 Idar-Oberstein
Germany

Telephone: 06781/980622 (or 46335)
e-mail: michael.galle@institut-biophysikalische-medizin.de

Abstract

In 1976, Morell and Rasche, the inventors of the classical bioresonance therapy (e.g. MORA) are postulating a weak, low-frequency electromagnetic field ($1-10^5$ Hz) in a human organism that was considered to induce important regulative functions. It is historically interesting that at the same time Popp and Ruth rediscovered the biophotons, an electromagnetic regulation field in the optical frequency range.

In the endogenous form of bioresonance the postulated oscillations are picked up by means of hand and foot electrodes and after an electronic inversion are transmitted back to the body for therapeutic purposes. Within the exogenous form, the postulated oscillations of bio-active substances, are transmitted after an electronic inversion (e.g. allergens) or amplification (e.g. nosodes) for therapeutic purposes to the human organism.

For about thirty years the exogenous bioresonance therapy has been used for therapy with children all over the world suffering from allergic diseases (e.g. bronchial asthma, allergic rhinitis, eczema).

As a summary and for the evaluation of clinical results in bioresonance therapy reports we have the following literature available: twelve non-controlled and five controlled clinical studies, which give clear evidence of the clinical effectiveness in allergy therapy with children. These trials were carried out by physicians and scientists in universities, hospitals and medical practices all over the world.

The twelve non-controlled (1471 patients) and three controlled studies (573 patients) are unrestrictedly positive according to the author's report. Two controlled studies (83 patients) were evaluated negative according to the author's conclusion. However, even in these reports there is some evidence of the bioresonance therapy's clinical effectiveness. Particularly remarkable in the results is the clear and strong dependence of the effectiveness with respect to the age of the proband in the trials. The younger the proband, the higher the effectiveness of bioresonance therapy.

In each trial no side effects were observed.

Conclusion: The greater majority of the performing scientists and physicians believe - on the basis of their investigations - that the classical bioresonance therapy is clinically effective in allergy therapy for children.

Definitions

Classical bioresonance therapy (e.g. MORA)


The classical bioresonance therapy is effected by use of devices with conventional physical-technical hardware (e.g. electronic components like electrodes, wires, electronic amplifiers). Weak electromagnetic oscillations in the range of 1 to 10^5 Hz (until now not measurable with technical detectors) from human beings and substances are postulated as a carrier of the information transfer. The postulated basic mechanism of therapy is the phase-constant electronic inversion of human and substance oscillations and its transmission to human beings. The bioresonance method was developed by F. Morell and E. Rasche from the electro acupuncture's medication-test.

These classical bioresonance devices have noticeable differences compared with bio-resonator devices and radionic (psycho biophysics) devices which have no conventional technical hardware. In the frame of these therapies and diagnostics the information transfer should be performed with "non-classical fields" or "consciousness-fields".

Allergy

The term “allergy” in the frame of this presentation is defined as a reaction of different nature by a substance after hypersensitivity has happened. Relevant is the allergic reaction on the level of clinical symptoms independent from skin- or blood tests. For the patients it does not matter if it is a “true allergy”, a “pseudo-allergy” or an “intolerance”. The bioresonance therapy works on the biophysical- not the biochemical level.

Principle of the exogenous and endogenous bioresonance therapy



Within the endogenous form of bioresonance (blue arrows) the postulated oscillations are picked up by means of hand and foot electrodes and after transmission by wires and phase-constant electronic inversion within the bioresonance device they are transmitted back to the human body by wires and electrodes for therapeutic purposes.

Within the exogenous form (red arrows), the postulated oscillations from bio-active substances (electronically stored or from native substances) are transmitted from electrodes by

means of wires (conductor) in the bioresonance device and after phase-constant electronic amplification (e.g. nosodes) or inversion (e.g. allergens) they are further transmitted by wire and electrodes to the human being or on a water alcohol mixture.

Clinical reports about exogenous bioresonance therapy within allergic diseases

The basic procedure of diagnosis and therapy in the presented clinical reports about allergic diseases:

1. Diagnosis: The allergen's oscillation is taken from a native-allergen placed in the input electrode or from an electronically stored allergen information. It is then inverted and transmitted to the patient. If the inverted allergen oscillation is within the scope of the electro-acupuncture measurement (EAP) in resonance with the patient, it (the most effective one) is used for therapy (= EAP/Bioresonance-Allergen-Test).
2. Therapy: The positive tested allergen oscillations are electronically inverted and transmitted to the patient in a pulse-pause-regime.

Source of reports:

Scientific databases (e.g. Medline, Amed, Embase), companies, cited literature in publications, bioresonance therapists.

Used devices:

The studies were carried out with the MORA or the BICOM device.

The trials were carried out in practices, hospitals and medical units at universities.

Non-controlled therapy studies with descriptive statistics

Conduct: Prospective, no anti allergic medication, avoidance of allergens during treatment, outcomes are the change of the clinical symptoms before and after treatment (sometimes immediately, sometimes up to one year) assessed from patients or physicians.

Results: In summary, twelve studies with 1471 patients show an effective rate (E) of 59.3% to 94.6% and a response rate (R) of 73.2% to 97.5% depending on the specific indication, patients age and duration of the diseases (see table). Some authors emphasized that this standardized regime of bioresonance therapy works better in children than in adults and better in acute than in chronic diseases. No side effects were observed.

Conclusion: All authors consider the bioresonance therapy to be clinically effective and worth applying on children owing to no side effects.

First author	Indication	Participants	E	R
Morell 1988	allergic skin and respiratory diseases, Pollinosis	190 Predominate adults	79.0%	?
Schumacher 1990/98	allergic skin and respiratory diseases	164 (200 cases) Predominate children	94%	?
Schumacher 1991/98	chronic Pollinosis	115 (145 cases) Predominate children	59.3%	93.8%
Hennecke 1994	allergic skin, respiratory and intestine diseases	200 Children and adults According to the author most of the patients had been treated in a conventional manner without success.	84.5%	?
Xu 2005	chronic urticaria	56 Predominate adults <u>Children</u> (0 – 15J, n = 10): <u>Adults</u> (16 – 68 J, n = 46): E (0-15J): 90.0%, E (16-30J): 69.2%, E (31-45J): 58.3%, E (46-60J): 46.7%, E (60-68J): 33.3%	60.7% 90.0% 54.3%	73.2% 100% 67.4%
Feng 2005	allergic skin and respiratory diseases	150 Only children (0 – 16 J)	94.6%	?
Du 2005	allergic skin diseases	79 Predominate children	89.9%	97.5%
Zhang 2005	chronic urticaria	56 Predominate children	66.6%	85.1%
Cheng 2008	allergic skin and respiratory diseases	32 Predominate children	77.7%	93.7%

Wen 2009	allergic skin and respiratory diseases	152 Children and adults According to the author 87 patients had been treated in a conventional manner without success.	75.0%	89.5%
Li 2009	Acute and chronic urticaria	108 Children and adults 69 chronic 35 acute	85.2% 76.8% 100%	96.3% 94.2% 100%
Herrmann 2009, Retro-spective	allergic skin and respiratory diseases, Pollinosis	169 Predominate adults According to the author most of the patients had been treated in a conventional manner without success.	61.0%	87.7%
In summary		Predominate adults (n = 3) mean standard deviation	66.9% 10.5%	80.5% 10.3%
In summary		Predominate children (n = 6) mean standard deviation	80.4% 15.0%	92.5% 5.3%

Effective rate (E): (cases of “clinically cured” + cases of “much improved”) / total cases (%)

Response rate (R): cases of “clinically cured” + cases of “much improved” + cases of “better”) / total cases (%)

Controlled therapy studies with positive results according to the authors conclusion

Chervinskaya 1997

Prospective therapy study with two groups:

Group 1: conventional therapy + bioresonance therapy

Group 2: conventional therapy

Conventional = glucocorticoid-therapy, anti-allergenic, etc.

The groups are identical regarding indication, sex and age.

Indication: allergic and respiratory diseases

Outcome: clinical symptoms (before and after treatment)

Participants: 101 adults (30J – 50J)

Results (only allergic diseases)

Bioresonance group	Very good	Good	Satis-factory	Not Satis-factory
Allergic bron-chial asthma n = 14	3	6	4	1
Allergic rhinitis n = 5	1	2	1	1
Atopic derma-titis, chronic urticaria, n = 4	0	2	1	1
Total (n = 23)	4 (17.4%)	10 (43.5%)	6 (26.1%)	3 13.0%)

With regard to the control group (N = 45) bioresonance therapy shows better therapeutic results in shorter time and a reduction of the used medicaments [no table with quantitative data in the report]

Authors conclusion: The clinical effectiveness of the bioresonance therapy is better than the conventional therapy and without side effects.

Yang 2004

Prospective therapy study with two groups:

Group 1: bioresonance therapy

Group 2: conventional therapy (glucocorticoid-therapy, anti- allergenics, according to GINA-concept)

The groups are identical regarding indication, sex and age.

Indication: allergic bronchial asthma

Outcome: clinical symptoms (before and 6 months after treatment)

Participants: 300 children (2 – 15 J)

Results

	Bioresonance-group (n = 213)	Conventional-group (n = 87)
	patients	patients
Cured (1)	92 (43.2%)	37 (42.5%)
Clear effective (2)	67 (31.4%)	17 (19.5%)
Effective (3)	23 (10.8%)	12 (13.8%)
Non effective	28 (13.1%)	21 (24.1%)
Effective rate (1 +2 + 3)	85.4%	75.8%

Conclusion of the authors: The clinical effectiveness of the bioresonance therapy is better than the conventional therapy and without side effects.

Huang 2005

Prospective, randomized therapy study with three groups:

Group 1: first diagnosis, no anti-allergens, bioresonance therapy

Group 2: resistant to therapy so far, no anti-allergens, bioresonance therapy

Group 3: first diagnosis, conventional therapy (glucocorticoid-therapy, anti asthmatic, etc.)

The groups are identical regarding indication, sex and age.

Indication: allergic rhinitis and allergic bronchial asthma

Outcome: clinical symptoms (before and 6 months after treatment)

Participants: 172 children (1 – 15 J)

Results

	n	Cured (1)	Clearly effective (2)	Non- effective (3)	Effective rate (1) + (2)
Group 1 Bioresonance, first	63	29 (46.0%)	25 (39.7%)	9 (14.3%)	85.7%
Group 2 Bioresonance, resistant	54	19 (35.2%)	24 (44.9%)	11 (20.4%)	79.6%
Group 3 Conventional, first	55	18 (32.7%)	20 (36.4%)	17 (30.9%)	69.1%

The differences in the distributions are not significant ($p > 0.05$, chi-square-test)

Conclusion of the authors: The bioresonance therapy has no side effects and is at least as clinically effective as the conventional therapy. It is recommended for children without conventional therapy success

Controlled therapy studies with negative results according to the authors conclusion

Kofler 1996

Prospective therapy study with two groups (single blind):

Group 1: active bioresonance therapy

Group 2: sham bioresonance therapy (placebo therapy)

No information about the equality of age and sex between the groups.

Indication: Pollinosis

Outcome: nasal provocation, duration of complaints, duration of taking up medicaments, subjective assessment of the participants (before, immediately after and 8 months after treatment and pollen period)

Participants: 51 (age?), 23 drop outs without explanation

Results

The nasal provocation shows no significant difference between placebo and verum.

Comparison with regard to days of complaints and taking up of medicaments (examples)

Group	Mean duration (days)	Median duration (days)	Standard-deviation	p
Complaints, total (eye, nose, bronchi)				
Placebo 9	33	19.95	28	
Verum 42	40.62	34.36	30	0.78
Days of taking Loratadin				
Placebo 9	3.89	4.51	3	
Verum 42	4.83	11.7	0	0.48

No significant differences in any parameter of duration of complaints and duration of taking up medicaments.

Subjective assessment of the effectiveness of treatment by the test subjects

	worse	equal	better	No complaints	N
Verum, total	11(26.1%)	9(21.4%)	17(40.4%)	5(11.9)	42
Verum, correct Diagnosis	0	5(11.9%)	3(7.1%)	3(7.1%)	11
Verum, wrong Diagnosis	11(26.1%)	4(9.5%)	14(33.3%)	2(4.8%)	31
Placebo	1(11.1%)	6(66.6%)	2(22.2%)	0	9

Significant differences between the groups.

Chi-square-test:

Verum (total) vs placebo p = 0.055

Verum (correct diagnosis in bioresonance test) vs placebo p = 0.248

Verum (wrong diagnosis in bioresonance test) vs placebo p = 0.012

[correct diagnosis in bioresonance test = the bioresonance test was in agreement with the skin test ("Prick-test");

wrong diagnosis in bioresonance test = the bioresonance test was not in agreement with the skin test ("Prick-test")]

Conclusion of the authors: The bioresonance therapy is not clinically effective. The contradiction between the results in the objective and subjective parameters is caused by placebo effects.

Schöni 1997

Prospective, randomized, double blind therapy study with two groups:

Group 1: active bioresonance therapy + conventional therapy (steroids, antibiotics, etc.)

Group 2: sham bioresonance therapy (placebo therapy) + conventional therapy (steroids, antibiotics, etc.)

The groups are equal with regard to indication, medication, sex and age.

Indication: atopic dermatitis

Outcome: clinical symptoms (skin score, pruritus score, sleep score) and cell markers in peripheral blood (before, immediately after and 8 months after treatment and pollen period)

Participants: 32 children (1.5 – 16.8J)

Results

No significant differences between the groups in blood IgE and cell markers.

No significant differences between the groups in the long-term clinical outcome. There are signs of improvement in the bioresonance group.

Short-term clinical outcome: Differences of the clinical symptoms before and after treatment (mean and standard deviation)

score	placebo (change)	bioresonance (change)	p (placebo vs bioresonance)
skin, total	6.7 +/- 8.2	12.5 +/- 12.6	p = 0.23 not significant
pruritus	0.5 +/- 1.4	1.3 +/- 2.1	p = 0.12 not significant
sleep	1.2 +/- 1.8	1.1 +/- 1.9	p = 0.92 not significant

There are signs of improvement in skin and pruritus score.

Conclusion of the authors: The bioresonance therapy is not clinically effective. No side effects were observed.

Conclusion

The twelve non-controlled (1471 patients) and three controlled studies (573 patients) are unrestrictedly positive according to the author's report. Two controlled studies (83 patients) had been evaluated negative according to the author's conclusion. However, even in these reports there is some evidence of the clinical effectiveness of classical bioresonance therapy.

Particularly remarkable in the results is the clear and strong dependence of the effectiveness with respect to the age of the proband in the trials. The younger the proband, the higher the effectiveness of bioresonance therapy.

In summary, the greater majority of the performing scientists and physicians believe - on the basis of their investigations - that the non invasive classical bioresonance therapy is clinically effective and worth applying in allergy therapy for children. Furthermore in no trial side effects were observed.

Epilogue

Further clinical studies verify the clinical effectiveness of bioresonance therapy in a broad range of indications (e.g. Maiko 2000, Nienhaus 2006) and in human in-vitro studies (e.g. Podchernyaeva 2008). These days Phitili et al. (2009) finished a randomized, double blind trial in “quitting smoking” which proves the bioresonance method.

A lot of investigations with animals and plants give evidence for the bioresonance method (e.g. Hutzschenreuter 1991, Benveniste 1998, Thomas 2000, Fedorowski 2004). On a physical level Korenbaum (2006) shows in a randomized and double blind trial that electronic copies of bioactive substances, done by the bioresonance method, are different from placebo electronic copies in the absorption spectra in the optical frequency range from 700 to 800 nm. *The broad spectrum of indications and the general biological efficiency in connection with the ability of electromagnetic storing of the specific biological and clinical information points to a fundamental biophysical mechanism of effectiveness on the electromagnetic level.*

References

- Benveniste J, Aissa J, Guillonnet D: Digital biology: Specificity of the digitized molecular signal. FASEB Journal 1998; 12: A412 (see in greater detail: www.digibio.com).
- Cheng CF, Wu YL, Tsai MH, Wu WF, Liu LL: A study to evaluate the efficacy of bioresonance therapy of MORA device on allergic symptoms. Clinical report 2008, Danshuei Township Public Health Center, Taipei County, Taiwan. Presented on the Second World Conference of Natural Medicine, Taipei, Oct. 24, 2008
- Chervinskaya AW, Gorelow AI, Nasarowa LW: MORA-Therapie bei respiratorischen und allergischen Erkrankungen. Clinical report 1997, Central Medical Department No. 122, University St. Petersburg.
- Du X, Liu Y, Yang J: Klinische Beobachtung über 79 Behandlungsfälle gegen allergische Hautkrankheiten mittels Bioresonanzgerät. Chinese Journal of Practice Medicine 2005; 4(5):259
- Fedorowski A, Steciwko A, Rabczynski J: Low-frequency electromagnetic stimulation may lead to regression of Morris Hepatoma in Buffalo rats. The Journal of Alternative and Complementary Medicine 2004; 10(2):251-260.
- Feng Y, Chen H, Li R, Liu L: Die neulich klinische Beobachtung der Heilwirkung mit Bioresonanztherapiegerät in 150 Fällen der Kinder-Allergiekkrankheit. Chinese Journal of Contemporary Paediatrics 2005; 7(3):257-258
- Hennecke J: Energetische Allergietherapie – Möglichkeiten und Erfahrungen mit der Bicom-Bioresonanztherapie. Ärztezeitschrift für Naturheilverfahren 1994; 35:427-432.
- Herrmann E: Untersuchung der Wirksamkeit der MORA-Bioresonanztherapie in einer internistischen Praxis. Clinical report 2009, Horn-Bad Meinberg, Germany (in preparation for publication).
- Huang S, Sun Z, Fang Y: Klinische Behandlung vom allergischen Schnupfen und Bronchialasthma der Kinder mit dem Bioresonanztherapiegerät. Zhejiang Medical Journal 2005; 27(6):457-458.
- Hutzschenreuter P, Brümmer H: Die Narbe, das Keloid und die MORA-Therapie. Therapeutikon 1991; 5(10):507-515.
- Kofler H, Ulmer H, Mechtler E, Falk M, Fritsch PO: Bioresonanz bei Pollinose – eine vergleichende Untersuchung zur diagnostischen und therapeutischen Wertigkeit. Allergologie 1996; 19(3):114-122.
- Korenbaum VI, Chernysheva TN, Apukthina TP, Sovetnikova LN: Absorption spectra of electronic-homoeopathic copies of homoeopathic nosodes and placebo have essential differences. Forschende Komplementärmedizin 2006; 13:294-297.

- Li Y, Liu H: Observation on clinical treatment result for both chronic and acute urticaria with MORA device. Chinese Journal of Clinical Dermatology 2009; 50 (3):128-129
- Maiko OJu, Gogoleva EF: Outpatient bioresonance treatment of gonarthrosis. *Terapevticheskii Arkhiv* 2000; 72 (12):50-53.
- Morell F: Allergietherapie mit dem MORA-Super – eine prospektive Praxisstudie. Clinical report 1988, Ottingen, Germany.
- Nienhaus J, Galle M: Placebokontrollierte Studie zur Wirkung einer standardisierten MORA Bioresonanztherapie auf funktionelle Magen-Darm-Beschwerden. *Forschende Komplementärmedizin* 2006 13:28-34
- Pihtili A, Cuhhadraroglu C, Kilicaslan Z, Issever H, Erkan F: The effectiveness of bioresonance method in quitting smoking. Clinical report 2009, Department of Medicine, University Istanbul, Turkey (in preparation for publication).
- Podcernyaeva RJa, Lopatina OA, Mikhailova GR, Baklanova OV, Danlibaeva GA, Gushina EA: Effect of exogenous frequency exposure on human cells. *Bulletin of Experimental Biology and Medicine* 2008; 146(1): 148-152
- Schöni MH, Nikolaizik WH, Schöni-Affolter F: Efficacy Trial of Bioresonance in Children with atopic dermatitis. *International Archives of Allergy and Immunology* 1997; 112: 238-246.
- Schumacher P: Biophysikalische Allergietherapie – Grundlagen und Ergebnisse. *Erfahrungsheilkunde* 1990; 39(12):812-817. Schumacher P: Biophysikalische Therapie der Allergien. pp 125-133, Stuttgart, Sonntag 1998.
- Schumacher P: Biophysikalische Therapie der Allergien. pp 147-154, Stuttgart, Sonntag 1998 (durchgeführt 1991).
- Thomas Y, Schiff M, Belkadi L, Jurgens P, Kahhak L, Benveniste J: Activation of human neutrophils by electronically transmitted phorbolmyristate acetate. *Medical Hypotheses* 2000; 54(1):33-39.
- Wen Q, Zhang C, Liu H: Allergy Disease Test and Therapy Result Observation with MORA-Super Biophysical Therapy Device. Clinical report 2009, Dermatology Section of Herbal Medical Hospital, Xingjiang, China (in preparation for publication).
- Xu M, Zheng M, Xu Y, Jang J, Zhang X: Klinische Beobachtung der Behandlung vom chronischen Nesselausschlag mit dem Bioresonanztherapiegerät; *China Journal of Leprosy and Skin Diseases* 2005; 21(7):533-534.
- Yang J, Zhang L: 300 Behandlungsbeispiele gegen Asthma mittels BICOM-Grätes für die Kinderpatienten. *Maternal and Child Health Care of China* 2004; 19(9):126-127
- Zhang X, Wang W, Liu Q: Klinische Beobachtung über 54 Behandlungsfälle gegen Nesselausschlag mittels BICOM Bioresonanztherapiegerät. *China Journal of Leprosy and Skin Diseases* 2005; 21(8):651.